Cantuzumab mertansine (SB-408075, huC242-DM1), an ADC, is an immunoconjugate of the potent maytansine derivative and the humanized monoclonal antibody (huC242) directed to CanAg. Cantuzumab mertansine has cytotoxic toward colon cancer cells and has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts.
Reinheit:
>95.0%
CAS Nummer:
[400010-39-1]
Target-Kategorie:
Drug-Linker Conjugates for ADC
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
